Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 435, 1169-1170 (30 June 2005) | doi:10.1038/4351169a; Published online 29 June 2005
Open Innovation Challenges
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
- More Challenges
- Powered by:
nature jobs
Molecular Diagnostic Pathologist
- Tulane University Health Sciences Center
- Tulane, Louisiana, USA
Senior Executive- Finance Corporate Office
- Rhydburg Pharmaceuticals
- Selaqui-Dehradun India
Cancer biology: Summing up cancer stem cells
Brian J. P. Huntly1 & D. Gary Gilliland1
Abstract
Are current cancer drugs targeted at the wrong kinds of cells? A pioneering approach to the development of treatments uses a mathematical model to follow how different types of tumour cells respond to therapy.
In this issue, Michor and colleagues (Dynamics of chronic myeloid leukaemia)1 address the vexing problem that although many cancer drugs dramatically reduce the size of tumours, most cancers will eventually recur, often fatally. The authors model the dynamic changes in populations of cancer cells during treatment, and their data fit with the theory that there is a small population of cells — 'cancer stem cells' — that are ultimately responsible for the growth of tumours and are resistant to current therapies.
- Brian J. P. Huntly is in the Department of Haematology, University of Cambridge, Cambridge CB2 2XY, UK, and D. Gary Gilliland is at Brigham and Women's Hospital and the Dana–Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Email: bjph2@cam.ac.uk
Email: ggilliland@rics.bwh.harvard.edu
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Targeted cancer treatment: resisting arrestNature Medicine News and Views (01 Oct 2006)
RESEARCH
Mycoplasma infection suppresses p53, activates NF-κB and cooperates with oncogenic Ras in rodent fibroblast transformationOncogene Original Article
PML targeting eradicates quiescent leukaemia-initiating cellsNature Article (19 Jun 2008)
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemiaNature Genetics Article (01 Jul 2009)
See all 33 matches for Research